These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 10699327)
1. Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1. O'Hagan DT; Ugozzoli M; Barackman J; Singh M; Kazzaz J; Higgins K; Vancott TC; Ott G Vaccine; 2000 Mar; 18(17):1793-801. PubMed ID: 10699327 [TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group. Keefer MC; Graham BS; McElrath MJ; Matthews TJ; Stablein DM; Corey L; Wright PF; Lawrence D; Fast PE; Weinhold K; Hsieh RH; Chernoff D; Dekker C; Dolin R AIDS Res Hum Retroviruses; 1996 May; 12(8):683-93. PubMed ID: 8744579 [TBL] [Abstract][Full Text] [Related]
3. HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine. McGuire EP; Fong Y; Toote C; Cunningham CK; McFarland EJ; Borkowsky W; Barnett S; Itell HL; Kumar A; Gray G; McElrath MJ; Tomaras GD; Permar SR; Fouda GG J Virol; 2018 Jan; 92(1):. PubMed ID: 29021402 [TBL] [Abstract][Full Text] [Related]
4. Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers. Kahn JO; Sinangil F; Baenziger J; Murcar N; Wynne D; Coleman RL; Steimer KS; Dekker CL; Chernoff D J Infect Dis; 1994 Nov; 170(5):1288-91. PubMed ID: 7963729 [TBL] [Abstract][Full Text] [Related]
5. Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit. Barnett SW; Rajasekar S; Legg H; Doe B; Fuller DH; Haynes JR; Walker CM; Steimer KS Vaccine; 1997 Jun; 15(8):869-73. PubMed ID: 9234536 [TBL] [Abstract][Full Text] [Related]
6. Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations. Newman MJ; Wu JY; Gardner BH; Anderson CA; Kensil CR; Recchia J; Coughlin RT; Powell MF Vaccine; 1997 Jun; 15(9):1001-7. PubMed ID: 9261947 [TBL] [Abstract][Full Text] [Related]
7. Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant. Wen Y; Trinh HV; Linton CE; Tani C; Norais N; Martinez-Guzman D; Ramesh P; Sun Y; Situ F; Karaca-Griffin S; Hamlin C; Onkar S; Tian S; Hilt S; Malyala P; Lodaya R; Li N; Otten G; Palladino G; Friedrich K; Aggarwal Y; LaBranche C; Duffy R; Shen X; Tomaras GD; Montefiori DC; Fulp W; Gottardo R; Burke B; Ulmer JB; Zolla-Pazner S; Liao HX; Haynes BF; Michael NL; Kim JH; Rao M; O'Connell RJ; Carfi A; Barnett SW PLoS One; 2018; 13(4):e0194266. PubMed ID: 29698406 [TBL] [Abstract][Full Text] [Related]
8. Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein. Dey AK; Burke B; Sun Y; Hartog K; Heeney JL; Montefiori D; Srivastava IK; Barnett SW Vaccine; 2012 Apr; 30(17):2749-59. PubMed ID: 22366638 [TBL] [Abstract][Full Text] [Related]
9. Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations. Vajdy M; Singh M; Kazzaz J; Soenawan E; Ugozzoli M; Zhou F; Srivastava I; Bin Q; Barnett S; Donnelly J; Luciw P; Adamson L; Montefiori D; O'Hagan DT AIDS Res Hum Retroviruses; 2004 Nov; 20(11):1269-81. PubMed ID: 15588349 [TBL] [Abstract][Full Text] [Related]
10. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. Bekker LG; Moodie Z; Grunenberg N; Laher F; Tomaras GD; Cohen KW; Allen M; Malahleha M; Mngadi K; Daniels B; Innes C; Bentley C; Frahm N; Morris DE; Morris L; Mkhize NN; Montefiori DC; Sarzotti-Kelsoe M; Grant S; Yu C; Mehra VL; Pensiero MN; Phogat S; DiazGranados CA; Barnett SW; Kanesa-Thasan N; Koutsoukos M; Michael NL; Robb ML; Kublin JG; Gilbert PB; Corey L; Gray GE; McElrath MJ; Lancet HIV; 2018 Jul; 5(7):e366-e378. PubMed ID: 29898870 [TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group. Graham BS; Keefer MC; McElrath MJ; Gorse GJ; Schwartz DH; Weinhold K; Matthews TJ; Esterlitz JR; Sinangil F; Fast PE Ann Intern Med; 1996 Aug; 125(4):270-9. PubMed ID: 8678389 [TBL] [Abstract][Full Text] [Related]
12. Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope. VanCott TC; Mascola JR; Loomis-Price LD; Sinangil F; Zitomersky N; McNeil J; Robb ML; Birx DL; Barnett S J Virol; 1999 Jun; 73(6):4640-50. PubMed ID: 10233923 [TBL] [Abstract][Full Text] [Related]
13. Adjuvant-Dependent Enhancement of HIV Env-Specific Antibody Responses in Infant Rhesus Macaques. Phillips B; Van Rompay KKA; Rodriguez-Nieves J; Lorin C; Koutsoukos M; Tomai M; Fox CB; Eudailey J; Dennis M; Alam SM; Hudgens M; Fouda G; Pollara J; Moody A; Shen X; Ferrari G; Permar S; De Paris K J Virol; 2018 Oct; 92(20):. PubMed ID: 30089691 [TBL] [Abstract][Full Text] [Related]
14. Immune response in rhesus macaques after mixed modality immunisations with DNA, recombinant adenovirus and recombinant gp120 from human immunodeficiency virus type 1. Vinner L; Therrien D; Wee E; Laursen I; Hanke T; Corbet SL; Fomsgaard A APMIS; 2006 Oct; 114(10):690-9. PubMed ID: 17004972 [TBL] [Abstract][Full Text] [Related]
15. Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120. Chirenje ZM; Laher F; Dintwe O; Muyoyeta M; deCamp AC; He Z; Grunenberg N; Laher Omar F; Seaton KE; Polakowski L; Woodward Davis AS; Maganga L; Baden LR; Mayer K; Kalams S; Keefer M; Edupuganti S; Rodriguez B; Frank I; Scott H; Stranix-Chibanda L; Gurunathan S; Koutsoukos M; Van Der Meeren O; DiazGranados CA; Paez C; Andersen-Nissen E; Kublin J; Corey L; Ferrari G; Tomaras G; McElrath MJ J Infect Dis; 2024 Aug; 230(2):e405-e415. PubMed ID: 37795976 [TBL] [Abstract][Full Text] [Related]
16. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120. AIDS Vaccine Evaluation Group 022 Protocol Team J Infect Dis; 2001 Feb; 183(4):563-70. PubMed ID: 11170981 [TBL] [Abstract][Full Text] [Related]
17. Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine. McFarland EJ; Borkowsky W; Fenton T; Wara D; McNamara J; Samson P; Kang M; Mofenson L; Cunningham C; Duliege AM; Sinangil F; Spector SA; Jimenez E; Bryson Y; Burchett S; Frenkel LM; Yogev R; Gigliotti F; Luzuriaga K; Livingston RA; J Infect Dis; 2001 Nov; 184(10):1331-5. PubMed ID: 11679925 [TBL] [Abstract][Full Text] [Related]
18. Enhancement of HIV-1 Env-Specific CD8 T Cell Responses Using Interferon-Stimulated Gene 15 as an Immune Adjuvant. Gómez CE; Perdiguero B; Falqui M; Marín MQ; Bécares M; Sorzano CÓS; García-Arriaza J; Esteban M; Guerra S J Virol; 2020 Dec; 95(2):. PubMed ID: 33115866 [TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and HIV-1 virus neutralization of MN recombinant glycoprotein 120/HIV-1 QS21 vaccine in baboons . Powell MF; Cleland JL; Eastman DJ; Lim A; Murthy K; Newman MJ; Nunberg JH; Weissburg RP; Vennari JC; Wrin T AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S105-8. PubMed ID: 7865282 [TBL] [Abstract][Full Text] [Related]
20. Safety and Immunogenicity of a DNA Vaccine With Subtype C gp120 Protein Adjuvanted With MF59 or AS01B: A Phase 1/2a HIV-1 Vaccine Trial. Garrett N; Dintwe O; Monaco CL; Jones M; Seaton KE; Church EC; Grunenberg N; Hutter J; deCamp A; Huang Y; Lu H; Mann P; Robinson ST; Heptinstall J; Jensen RL; Pantaleo G; Ding S; Koutsoukos M; Hosseinipour MC; Van Der Meeren O; Gilbert PB; Ferrari G; Andersen-Nissen E; McElrath MJ; Tomaras GD; Gray GE; Corey L; Kublin JG; J Acquir Immune Defic Syndr; 2024 Aug; 96(4):350-360. PubMed ID: 38916429 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]